Pituitary adenylate cyclase-activating peptide (PACAP): Assessment of dipeptidyl peptidase IV degradation, insulin-releasing activity and antidiabetic potential

Peptides

Volumn 27, Issue 6, 2006, Pages 1349-1358

  Green, B D ^a   Irwin, N ^a   Flatt, P R ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

Diabetes; Dipeptidyl peptidase IV; Glucose homeostasis; Insulin secretion; PACAP

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; GLUCOSE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE(1-27); HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE(1-38); UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME DEGRADATION; GLUCOSE BLOOD LEVEL; INSULIN LIKE ACTIVITY; INSULIN RELEASE; INSULIN RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, CD26; BLOOD GLUCOSE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HYPOGLYCEMIC AGENTS; INSULIN; MICE; MICE, OBESE; MOLECULAR SEQUENCE DATA; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TIME FACTORS;

EID: 33646814910     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2005.11.010     Document Type: Article

References (27)

1. Ahren B., and Hughes T.E. Inhibition of dipeptidyl peptidase-4 augments insulin secretion in response to exogenously administered glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, pituitary adenylate cyclase-activating polypeptide, and gastrin-releasing peptide in mice. Endocrinology 146 (2005) 2055-2059
2. Arimura A., and Shioda S. Pituitary adenylate cyclase activating polypeptide (PACAP) and its receptors: neuroendocrine and endocrine interaction. Front Neuroendocrinol 16 (1995) 53-88
3. Bailey C.J., Flatt P.R., and Atkins T.W. Influence of genetic background and age on the expression of the obese hyperglycaemic syndrome in Aston ob/ob mice. Int J Obes 6 (1982) 11-21
4. Bertrand G., Puech R., Maisonnasse Y., Bockaert J., and Loubatieres-Mariani M.M. Comparative effects of PACAP and VIP on pancreatic endocrine secretions and vascular resistance in rat. Br J Pharmacol 117 (1996) 764-770
5. Burington R.S. Handbook of Mathematical Tables and Formulas (1973), McGraw-Hill, New York
6. Filipsson K., Holst J.J., and Ahren B. PACAP contributes to insulin secretion after gastric glucose gavage in mice. Am J Physiol Regul Integr Comp Physiol 279 (2000) R424-R432
7. Filipsson K., Pacini G., Scheurink A.J., and Ahren B. PACAP stimulates insulin secretion but inhibits insulin sensitivity in mice. Am J Physiol 274 (1998) E834-E842
8. Flatt P.R., and Bailey C.J. Abnormal plasma glucose and insulin responses in heterozygous lean (ob/+) mice. Diabetologia 20 (1981) 573-577
9. Fridolf T., Sundler F., and Ahren B. Pituitary adenylate cyclase-activating polypeptide (PACAP): occurrence in rodent pancreas and effects on insulin and glucagon secretion in the mouse. Cell Tissue Res 269 (1992) 275-279
10. Gray S.L., Cummings K.J., Jirik F.R., and Sherwood N.M. Targeted disruption of the pituitary adenylate cyclase-activating polypeptide gene results in early postnatal death associated with dysfunction of lipid and carbohydrate metabolism. Mol Endocrinol 15 (2001) 1739-1747
11. Green B.D., Gault V.A., O'Harte F.P.M., and Flatt P.R. Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents. Curr Pharm Des 10 (2004) 3651-3662
12. McClenaghan N.H., Barnett C.R., Ah-Sing E., Abdel-Wahab Y.H., O'Harte F.P.M., Yoon T.W., et al. Characterization of a novel glucose-responsive insulin-secreting cell line, BRIN-BD11, produced by electrofusion. Diabetes 45 (1996) 1132-1140
13. McClenaghan N.H., and Flatt P.R. Physiological and pharmacological regulation of insulin release: insights offered through exploitation of insulin-secreting cell lines. Diabetes Obes Metab 1 (1999) 137-150
14. Miyata A., Arimura A., Dahl R.R., Minamino N., Uehara A., Jiang L., et al. Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem Biophys Res Commun 164 (1989) 567-574
15. Robberecht P., Woussen-Colle M.C., De Neef P., Gourlet P., Buscail L., Vandermeers A., et al. The two forms of the pituitary adenylate cyclase activating polypeptide (PACAP (1-27) and PACAP (1-38)) interact with distinct receptors on rat pancreatic AR 4-2J cell membranes. FEBS Lett 286 (1991) 133-136
16. Sekiguchi Y., Kasai K., Hasegawa K., Suzuki Y., and Shimoda S. Glycogenolytic activity of pituitary adenylate cyclase activating polypeptide (PACAP) in vivo and in vitro. Life Sci 55 (1994) 1219-1228
17. Sherwood N.M., Krueckl S.L., and McRory J.E. The origin and function of the pituitary adenylate cyclase-activating polypeptide (PACAP)/glucagon superfamily. Endocr Rev 21 (2000) 619-670
18. Tomimoto S., Hashimoto H., Shintani N., Yamamoto K., Kawabata Y., Hamagami K., et al. Overexpression of pituitary adenylate cyclase-activating polypeptide in islets inhibits hyperinsulinemia and islet hyperplasia in agouti yellow mice. J Pharmacol Exp Ther 309 (2004) 796-803
19. Tornoe K., Hannibal J., Fahrenkrug J., and Holst J.J. PACAP-(1-38) as neurotransmitter in pig pancreas: receptor activation revealed by the antagonist PACAP-(6-38). Am J Physiol 273 (1997) G436-G446
20. Vandermeers A., Vandenborre S., Hou X., de Neef P., Robberecht P., Vandermeers-Piret M.C., et al. Antagonistic properties are shifted back to agonistic properties by further N-terminal shortening of pituitary adenylate-cyclase-activating peptides in human neuroblastoma NB-OK-1 cell membranes. Eur J Biochem 208 (1992) 815-819
21. Vaudry D., Gonzalez B.J., Basille M., Yon L., Fournier A., and Vaudry H. Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. Pharmacol Rev 52 (2000) 269-324
22. Yada T., Sakurada M., Filipsson K., Kikuchi M., and Ahren B. Intraperitoneal PACAP administration decreases blood glucose in GK rats, and in normal and high fat diet mice. Ann N Y Acad Sci 921 (2000) 259-263
23. Yada T., Sakurada M., Ihida K., Nakata M., Murata F., Arimura A., et al. Pituitary adenylate cyclase activating polypeptide is an extraordinarily potent intra-pancreatic regulator of insulin secretion from islet beta-cells. J Biol Chem 269 (1994) 1290-1293
24. Yada T., Sakurada M., Ishihara H., Nakata M., Shioda S., Yaekura K., et al. Pituitary adenylate cyclase-activating polypeptide (PACAP) is an islet substance serving as an intra-islet amplifier of glucose-induced insulin secretion in rats. J Physiol 505 (1997) 319-328
25. Yamamoto K., Hashimoto H., Tomimoto S., Shintani N., Miyazaki J., Tashiro F., et al. Overexpression of PACAP in transgenic mouse pancreatic beta-cells enhances insulin secretion and ameliorates streptozotocin-induced diabetes. Diabetes 52 (2003) 1155-1162
26. Yokota C., Kawai K., Ohashi S., Watanabe Y., and Yamashita K. PACAP stimulates glucose output from the perfused rat liver. Peptides 16 (1995) 55-60
27. Zhu L., Tamvakopoulos C., Xie D., Dragovic J., Shen X., Fenyk-Melody J.E., et al. The role of dipeptidyl peptidase IV in the cleavage of glucagon family peptides: in vivo metabolism of pituitary adenylate cyclase activating polypeptide-(1-38). J Biol Chem 278 (2003) 22418-22423